 |
|
Single-Donor, Marginal-Dose Islet Transplantation in Patients With Type 1 Diabetes
Bernhard J. Hering, MD;
Raja Kandaswamy, MD;
Jeffrey D. Ansite, BS;
Peter M. Eckman, MD;
Masahiko Nakano, MD, PhD;
Toshiya Sawada, MD;
Ippei Matsumoto, MD, PhD;
Sung-Hee Ihm, MD;
Hui-Jian Zhang, MD;
Jamen Parkey, PA-C, MPH;
David W. Hunter, MD;
David E. R. Sutherland, MD, PhD
JAMA. 2005;293:830-835.
Context Islet allografts from 2 to 4 donors can reverse type 1 diabetes. However, for islet transplants to become a widespread clinical reality, diabetes reversal must be achieved with a single donor to reduce risks and costs and increase the availability of transplantation.
Objective To assess the safety of a single-donor, marginal-dose islet transplant protocol using potent induction immunotherapy and less diabetogenic maintenance immunosuppression in recipients with type 1 diabetes. A secondary objective was to assess the proportion of islet transplant recipients who achieve insulin independence in the first year after single-donor islet transplantation.
Design, Setting, and Participants Prospective, 1-year follow-up trial conducted July 2001 to August 2003 at a single US center and enrolling 8 women with type 1 diabetes accompanied by recurrent hypoglycemia unawareness or advanced secondary complications.
Interventions Study participants underwent a primary islet allotransplant with 7271 (SD, 1035) islet equivalents/kg prepared from a single cadaver donor pancreas. Induction immunosuppression was with antithymocyte globulin, daclizumab, and etanercept. Maintenance immunosuppression consisted of mycophenolate mofetil, sirolimus, and no or low-dose tacrolimus.
Main Outcome Measures Safety (assessed by monitoring the severity and duration of adverse events) and efficacy (assessed by studying the recipients’ insulin requirements, C-peptide levels, oral and intravenous glucose tolerance results, intravenous arginine stimulation responses, glycosylated hemoglobin levels, and hypoglycemic episodes) associated with the study transplant protocol.
Results There were no serious, unexpected, or procedure- or immunosuppression-related adverse events. All 8 recipients achieved insulin independence and freedom from hypoglycemia. Five remained insulin-independent for longer than 1 year. Graft failure in 3 recipients was preceded by subtherapeutic sirolimus exposure in the absence of measurable tacrolimus trough levels.
Conclusions The tested transplant protocol restored insulin independence and protected against hypoglycemia after single-donor, marginal-dose islet transplantation in 8 of 8 recipients. These results may be related to improved islet engraftment secondary to peritransplant administration of antithymocyte globulin and etanercept. These findings may have implications for the ongoing transition of islet transplantation from clinical investigation to routine clinical care.
Author Affiliations: Diabetes Institute for Immunology and Transplantation and Department of Surgery; and Department of Radiology (Dr Hunter), University of Minnesota, Minneapolis.
RELATED LETTERS
Single-Donor Islet Transplantation for Diabetes
Craig V. Smith
JAMA. 2005;294(12):1488.
EXTRACT
| FULL TEXT
Single-Donor Islet Transplantation for Diabetes—Reply
Bernhard J. Hering and David E. R. Sutherland
JAMA. 2005;294(12):1488-1489.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The Caspase Selective Inhibitor EP1013 Augments Human Islet Graft Function and Longevity in Marginal Mass Islet Transplantation in Mice
Emamaullee et al.
Diabetes 2008;57:1556-1566.
ABSTRACT
| FULL TEXT
Metabolic and Immunological Features of the Failing Islet-Transplanted Patient
Fiorina et al.
Diabetes Care 2008;31:436-438.
ABSTRACT
| FULL TEXT
Pancreatic Islet Cell Transplantation: Update and New Developments
Onaca et al.
Nutr Clin Pract 2007;22:485-493.
ABSTRACT
| FULL TEXT
Kidney Function After Islet Transplant Alone in Type 1 Diabetes: Impact of immunosuppressive therapy on progression of diabetic nephropathy
Maffi et al.
Diabetes Care 2007;30:1150-1155.
ABSTRACT
| FULL TEXT
Cell-Permeable Pentapeptide V5 Inhibits Apoptosis and Enhances Insulin Secretion, Allowing Experimental Single-Donor Islet Transplantation in Mice
Rivas-Carrillo et al.
Diabetes 2007;56:1259-1267.
ABSTRACT
| FULL TEXT
Caspase Inhibitor Therapy Enhances Marginal Mass Islet Graft Survival and Preserves Long-Term Function in Islet Transplantation
Emamaullee et al.
Diabetes 2007;56:1289-1298.
ABSTRACT
| FULL TEXT
Islet cell transplantation
Srinivasan et al.
Postgrad. Med. J. 2007;83:224-229.
ABSTRACT
| FULL TEXT
Superiority of Small Islets in Human Islet Transplantation
Lehmann et al.
Diabetes 2007;56:594-603.
ABSTRACT
| FULL TEXT
Prediction of Clinical Outcome in Islet Allotransplantation
Bertuzzi and Ricordi
Diabetes Care 2007;30:410-417.
FULL TEXT
Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft
Keymeulen et al.
Proc. Natl. Acad. Sci. USA 2006;103:17444-17449.
ABSTRACT
| FULL TEXT
Overcoming the Challenges Now Limiting Islet Transplantation: A Sequential, Integrated Approach
PILEGGI et al.
Ann. N. Y. Acad. Sci. 2006;1079:383-398.
ABSTRACT
| FULL TEXT
International Trial of the Edmonton Protocol for Islet Transplantation.
Shapiro et al.
NEJM 2006;355:1318-1330.
ABSTRACT
| FULL TEXT
Effect of donor age on function of isolated human islets.
Ihm et al.
Diabetes 2006;55:1361-1368.
ABSTRACT
| FULL TEXT
Microencapsulated Pancreatic Islet Allografts Into Nonimmunosuppressed Patients With Type 1 Diabetes: First two cases
Calafiore et al.
Diabetes Care 2006;29:137-138.
FULL TEXT
Single-Donor Islet Transplantation for Diabetes
Smith
JAMA 2005;294:1488-1488.
FULL TEXT
Saving islets from allograft rejection
Strom
Proc. Natl. Acad. Sci. USA 2005;102:12651-12652.
FULL TEXT
Mycophenolate Mofetil in Islet Cell Transplant: Variable Pharmacokinetics but Good Correlation Between Total and Unbound Concentrations
Jacobson et al.
J Clin Pharmacol 2005;45:901-909.
ABSTRACT
| FULL TEXT
Five-Year Follow-Up After Clinical Islet Transplantation
Ryan et al.
Diabetes 2005;54:2060-2069.
ABSTRACT
| FULL TEXT
Medical Applications of Biotechnology
Fontanarosa and DeAngelis
JAMA 2005;293:866-867.
FULL TEXT
|
